通化金马新药进入最后审评环节，近期业绩已披露

Group 1 - The core point of the article is that Tonghua Golden Horse (000766) has completed the comprehensive review of its Class 1 chemical new drug, Amber Dihydroaminoacridine Tablets, and is now in the final review stage, which is a significant development to watch [1] Group 2 - The company reported its financial performance based on the Q3 2025 data, showing revenue of 892 million yuan and a net profit attributable to shareholders of 24.96 million yuan [2]